RxSight, Inc. Announces Pricing for Public Offering of Common Stock

ALISO VIEJO, Calif., May 8, 2024 (GLOBE NEWSWIRE) — (NASDAQ:RXST) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality personalized vision to patients after cataract surgery, today announced that it has priced its underwritten public offering. RxSight plans to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to 267,857 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares must be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead manager of the offering and as representative of the underwriters. JP Morgan is also acting as book-running manager for the offering. BTIG acts as co-manager of the offering.

RxSight intends to use the net proceeds from the offering for continued business and marketing expansion, including international expansion, financing of product development, research and clinical development, as well as for fundraising. turnover and general business needs.

RxSight filed an automatic shelf registration statement on Form S-3 relating to the shares of its common stock offered in the public offering described above with the Securities and Exchange Commission (the “SEC”) on May 8, 2024, which automatically entered into force upon filing. . RxSight filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the SEC on May 8, 2024. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with of the SEC and will be available on the SEC’s website at www. .sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus may also be obtained from: BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, by telephone at (800) 294-1322 or by email at [email protected] or JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at [email protected].

The story continues

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be illegal before registration. or qualification under the securities laws of any such state or other jurisdiction. The offering may only be made by means of a prospectus supplement and the accompanying prospectus.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality personalized vision to patients after cataract surgery. The RxSight® Light Adjustable Lens System, consisting of the RxSight Light® Adjustable Lens (LAL®/LAL+™, collectively “LAL”), the RxSight Light Distribution Device (LDD™) and accessories, is the first and only commercially available intraocular lens. (IOL) that can be adjusted after surgery, allowing doctors to customize and provide high-quality vision to patients after cataract surgery.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expectations regarding the anticipated consummation and timing of closing of the public offering and the anticipated use of proceeds net of the public purchase offer. offer. The risks and uncertainties associated with these efforts include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions associated with the public offering. Investors should consider the risks and uncertainties contained in our filings with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 6, 2024, in the preliminary prospectus supplement relating to the public offering filed with the SEC on May 8, 2024 and in the final prospectus supplement to be filed with the SEC, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking information presented in this press release is not a guarantee of future events and that actual events may differ materially from those described or implied by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “could”, “would”, “anticipate”, “intend”. of”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential” or “continue” or the negative of these terms and other similar terminologies. Any forward-looking information presented in this press release is presented only as of the date of this press release, and we undertake no obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events Or other.

Company contact:
Shelley B. Thunen
Financial director
[email protected]

Investor Relations Contact:
Olivier Moravcevic
Vice President, Investor Relations
[email protected]